With 1.68 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.23 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $45.16 whereas the lowest price it dropped to was $42.54. The 52-week range on EXAS shows that it touched its highest point at $79.62 and its lowest point at $40.62 during that stretch. It currently has a 1-year price target of $68.96. Beta for the stock currently stands at 0.93.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EXAS was down-trending over the past week, with a drop of -0.80%, but this was down by -8.65% over a month. Three-month performance dropped to -20.71% while six-month performance fell -34.59%. The stock lost -36.71% in the past year, while it has lost -20.70% so far this year. A look at the trailing 12-month EPS for EXAS yields -5.56 with Next year EPS estimates of 0.61. For the next quarter, that number is -0.33. This implies an EPS growth rate of 93.91% for this year and 277.87% for next year.
Float and Shares Shorts:
At present, 185.62 million EXAS shares are outstanding with a float of 182.94 million shares on hand for trading. On 2025-03-14, short shares totaled 10.6 million, which was 571.0 higher than short shares on 1739491200. In addition to Mr. Kevin T. Conroy J.D. as the firm’s Chairman of the Board & CEO, Mr. Jake Orville MBA serves as its Executive VP & GM of Screening.
Institutional Ownership:
Through their ownership of 1.0061799 of EXAS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, EXAS reported revenue of $713424000.0 and operating income of -$38068000.0. The EBITDA in the recently reported quarter was $13629000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EXAS since 16 analysts follow the stock currently. There are 13 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With EXAS analysts setting a high price target of 86.0 and a low target of 52.0, the average target price over the next 12 months is 68.47125. Based on these targets, EXAS could surge 93.0% to reach the target high and rise by 16.7% to reach the target low. Reaching the average price target will result in a growth of 53.66% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.09963 being high and -$1.22503 being low. For EXAS, this leads to a yearly average estimate of -$1.15751. Based on analyst estimates, the high estimate for the next quarter is $0.23 and the low estimate is $0.02. The average estimate for the next quarter is thus $0.1.
